[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100483595":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":20,"collaborators":10,"id":24,"slug":10,"hasResults":25,"nctId":26,"briefTitle":27,"officialTitle":27,"acronym":28,"eligibilityCriteria":29,"healthyVolunteers":25,"sex":30,"minAge":31,"maxAge":32,"enrollmentInfo":33,"targetDuration":36,"studyType":37,"phases":10,"briefSummary":38,"conditions":39,"keywords":10,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":10},{"fullName":5,"class":6},"AZ Sint-Jan AV","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"TEER",null,"Patients with tricuspid valve regurgitation eligible for transcatheter edge-to-edge repair (TEER)",[13],"Procedure: Transcatheter edge-to-edge repair (TEER)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","Transcatheter edge-to-edge repair (TEER)","Minimally invasive transcatheter-based edge-to-edge repair technique for tricuspid regurgitation",[9],{"type":21,"investigatorFullName":22,"investigatorTitle":23,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Jan Van der Heyden","Principal Investigator","100483595",false,"NCT05577078","TriBEL Registry: National Belgian Registry of Percutaneous Tricuspid Valve Repair Using a Transcatheter Edge-to-edge Repair Technique","TriBEL","Inclusion Criteria:\n\n* At least 18 years old\n* Eligible for TEER procedure\n* Informed consent signed\n\nExclusion Criteria:\n\n* Unwilling to provide informed consent","ALL","18 Years","110 Years",{"count":34,"type":35},120,"ESTIMATED","5 Years","OBSERVATIONAL","In this study, patients who have undergone or will undergo a transcatheter edge-to-edge repair (TEER) for tricuspid valve regurgitation (TR) will be followed up for 5 years. The goal of this prospective and retrospective, observational, non-randomized, multicenter registry is to confirm that TEER is a feasible, safe and effective treatment option for TR and to evaluate the long-term efficacy and safety of TEER.\n\nThe main endpoints are:\n\n* Change in tricuspid regurgitation grade: number of patients with a reduction in tricuspid regurgitation score by at least one grade\n* Composite of major adverse event: number of patients with composite of major adverse event (cardiovascular mortality, acute kidney injury, myocardial infarction, stroke or TIA, coronary revascularization, new onset AF or ventricular arrhythmia)",[40],"Tricuspid Valve Regurgitation","NOT_YET_RECRUITING","2022-10-10",{"date":44,"type":45},"2022-10-13","ACTUAL",{"date":47,"type":35},"2023-01-01",{"date":49,"type":35},"2029-12-31",{"name":5,"class":6}]